This list provides a summary of recent patent publications from April 2023 to February 15, 2024, focusing on scientific information. Please note that it may not include all patent publications related to PROTACs (PROteolysis TArgeting Chimeras). Continuation application publications are excluded.1. RNA-dependent RNA polymerase (RdRp)
- Target Disease: Herpes viruses
- Applicant/Assignee: Wuhan University WHU
- Reference: ProTAC compound of Reidesciclovir or intermediate thereof, preparation method, and application of anti-EV 71
2. Glutathione Peroxidase 4 (GPX4)
- Target Disease: Cancer
- Applicant/Assignee: Peking University
- Reference: GPX4 protein degrading agent, preparation method
3. Janus Kinase (JAK)
- Target Disease: Inflammatory skin diseases
- Applicant/Assignee: Shanghai Dermatology Hospital
- Reference: Novel application of JAK degrading agent based on PROTAC technology
4. Androgen Receptor (AR)
- Target Disease: Prostate cancer
- Applicant/Assignee: Montelino Therapeutics Inc
- Reference: Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
5. Hematopoietic Progenitor Kinase 1 (HPK1)
- Target Disease: Cancer
- Applicant/Assignee: China Pharmaceutical University
- Reference: Benzopyrimidine and phentriazine hematopoietic progenitor cell kinase 1 degradation agent
6. Protein FEM-1 homolog B (FEM1B)
- Target Disease: Cancer
- Applicant/Assignee: University of California
- Reference: Fem1b protein binding agents and uses thereof
7. Androgen Receptor (AR)
- Target Disease: Prostate cancer
- Applicant/Assignee: Montelino Therapeutics
- Reference: Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
8. Aurora A-Kinase
- Target Diseases: Leukemia, neuroblastoma, hepatocellular carcinoma, osteosarcoma
- Applicant/Assignee: Julius Maximilians Universitaet Wuerzburg
- Reference: Proteolysis targeting chimera (PROTAC) for degradation of Aurora A-kinase
9. Cereblon
- Target Disease: Multiple human diseases
- Applicant/Assignee: C4 Therapeutics
- Reference: Spirocyclic compounds
10. ABL Kinase
- Target Disease: Cancer
- Applicant/Assignee: Kymera Therapeutics
- Reference: Protein degraders and uses thereof
11. Multiple Protein Targets
- Target Disease: Cancer
- Applicant/Assignee: Orionis Biosciences
- Reference: Bifunctional agents for protein recruitment and/or degradation
12. Albumin Nanoparticles-based Delivery of PROTAC
- Target Disease: Multiple human diseases
- Applicant/Assignee: January Therapeutics
- Reference: Nanoparticle compositions
13. Asialoglycoprotein Receptor (ASGPR)
- Target Disease: Cancer
- Applicant/Assignee: Avilar Therapeutics
- Reference: ASGPR-binding compounds for the degradation of extracellular proteins
14. SMARCA2/SMARCA4 (SWI/SNF Related Matrix Associated Actin Dependent Regulator Of Chromatin Subfamily A Member 2/4)
- Target Disease: Cancer
- Applicant/Assignee: Dana Farber Cancer Institute
- Reference: Compounds, compositions, and methods for protein degradation
15. Tau Protein
- Target Disease: Alzheimer’s disease
- Applicant/Assignee: Arvinas Operations
- Reference: Compounds and methods for the targeted degradation of IRAK-4
16. SMARCA2/SMARCA4
- Target Disease: Cancer
- Applicant/Assignee: Amgen
- Reference: SMARCA2-VHL degraders
17. Bromodomain Containing 4 (BRD4), Polo Like Kinase 1 (PLK1), FK506 Binding Protein 12 (FKBP12)
- Target Diseases: Parkinson’s disease, Alzheimer’s disease, or cancer mediated by FKBP12
- Applicant/Assignee: Dana Farber Cancer Institute
- Reference: Methods to induce targeted protein degradation through bifunctional molecules
18. Tumor-associated Protein using Bio-PROTACs
- Target Disease: Cancer
- Applicant/Assignee: Purecodon Hong Kong Biopharma
- Reference: Circular RNA molecule and use thereof in targeted degradation of protein of interest
19. Hematopoietic Progenitor Kinase 1 (HPK1)
- Target Disease: Cancer
- Applicant/Assignee: National Jewish Health
- Reference: Heterobifunctional compounds as degraders of HPK1
20. Argininosuccinate Synthetase 1 (ASS1)
- Target Disease: Cancer
- Applicant/Assignee: Orionis Biosciences
- Reference: Modulation of protein degradation
21. Bromodomain-containing Protein 4 (BRD4)
- Target Disease: Cancer
- Applicant/Assignee: Yale University, Arvinas Operations
- Reference: Compounds and methods for the targeted degradation of bromodomain-containing proteins
22. Rapidly Accelerated Fibrosarcoma (RAF)
- Target Disease: Cancer
- Applicant/Assignee: Yale University, Arvinas Operations
- Reference: Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
23. Signal Transducer And Activator Of Transcription 3 (STAT3) and Signal Transducer And Activator Of Transcription 1 (STAT1)
- Target Disease: Cancer
- Applicant/Assignee: University of Michigan
- Reference: Small molecule degraders of STAT3
24. Cyclic-AMP Response Element Binding Protein (CBP) and/or Adenoviral E1A Binding Protein of 300 kDa (CBP/P300)
- Target Disease: Multiple diseases
- Applicant/Assignee: Cullgen Shanghai
- Reference: CBP and/or P300 degradation compounds and methods of use
25. Androgen Receptors
- Target Disease: Cancer
- Applicant/Assignee: University of British Columbia, Essa Pharma
- Reference: Androgen receptor modulators and methods for use as PROTAC ligands
26. HMG-CoA Reductase
- Target Disease: Cancer
- Applicant/Assignee: Uppthera
- Reference: HMG-CoA Reductase degradation inducing compound
27. Protein Tyrosine Kinase 6 (PTK6)
- Target Disease: Cancer
- Applicant/Assignee: National Jewish Health
- Reference: PTK6 degradation/disruption compounds and methods of use
28. Androgen Receptor
- Target Disease: Cancer
- Applicant/Assignee: Arvinas Operations
- Reference: Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
29. Interleukin-1 Receptor (IL-1R) Associated Kinase (IRAK)
- Target Disease: Multiple diseases
- Applicant/Assignee: Kymera Therapeutics
- Reference: IRAK degraders and uses thereof
30. Protein Kinases
- Target Disease: Multiple diseases
- Applicant/Assignee: Dana Farber Cancer Institute
- Reference: Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand
31. BCR-ABL
- Target Disease: Cancer
- Applicant/Assignee: Yunnan University
- Reference: Novel PROTAC compound and application thereof in anti-cancer drugs
32. Protein Kinase B or Akt (PKB/Akt)
- Note: Chaperone-mediated autophagy (CMA)
- Target Disease: Cancer
- Reference: KFERQ sequence-based blue light control protein degradation system
33. Tau
- Target Disease: Alzheimer’s disease
- Applicant/Assignee: West China Hospital of Sichuan University
- Reference: HL compound based on PROTAC principle
34. Estrogen Receptors
- Target Disease: Cancer
- Applicant/Assignee: Arvinas Operations
- Reference: Estrogen receptor proteolytic modulators
35. Tyrosine-protein Kinase Met (c-Met)/Hepatocyte Growth Factor Receptor (HGFR)
- Target Disease: Cancer
- Applicant/Assignee: Innocure Therapeutics
- Reference: Derivatives of Piperidinedione
36. Beta-amyloid Tau Protein
- Target Disease: Alzheimer’s disease
- Applicant/Assignee: University Industry Foundation UIF of Yonsei University, Daegu Gyeongbuk Medical Innovation Foundation
- Reference: Pyrrolidine derivatives and pharmaceutical composition for treating or preventing beta amyloid or tau protein associated disease
37. Androgen Receptor (AR)
- Target Disease: Cancer, Kennedy’s disease
- Applicant/Assignee: Hefei Comprehensive National Science Center Big Health Research Institute
- Reference: Degradation agent, preparation method, and application thereof
38. Brahma-related Gene 1 (BRG1)/ATP-dependent Chromatin Remodeler SMARCA4
- Target Disease: Type 2 diabetes
- Applicant/Assignee: Third Xiangya Hospital of Central South University
- Reference: Application of ACBI1
39. Androgen Receptor (AR)
- Target Disease: Breast cancer
- Applicant/Assignee: Jiangxi Jemincare Group Co Ltd, Shanghai Jemincare Pharmaceuticals Co Ltd
- Reference: Phthalazinone compound, preparation method, and medical use thereof
40. BET (Bromodomain and Extra-terminal Domain) Family Proteins
- Target Disease: Cancer
- Applicant/Assignee: China Pharmaceutical University
- Reference: Dendrimer PAMAM-G5-TCO and preparation method and application thereof
41. Zinc Finger AN1-Type Containing 5 (ZFAND5), PCLAF, PCNA Clamp Associated Factor (PCALF), ETS Proto-Oncogene 1 (ETS1)
- Target Disease: Cancer
- Applicant/Assignee: Guizhou Medical University
- Reference: Diartemisinin derivatives, preparation method, and application thereof
42. Proliferating Cell Nuclear Antigen (PCNA)
- Target Disease: Cancer
- Applicant/Assignee: Xishan Institute of Applied Biotechnology Nanjing University Wuxi
- Reference: Bacterium for degrading intracellular tumor proliferation protein
43. Bromodomain Containing 4 (BRD4) Protein
- Target Disease: Cancer
- Applicant/Assignee: Innocure Therapeutics
- Reference: Derivatives of Piperidinedione
44. Membrane Proteins
- Target Disease: Cancer
- Applicant/Assignee: Zhejiang University ZJU
- Reference: Antibody degrading molecule and application thereof
45. Bruton’s Tyrosine Kinase (BTK)
- Target Disease: Cancer, Autoimmune disorders
- Applicant/Assignee: Endotarget EnhancedBio
- Reference: Compounds and methods for the targeted degradation of Bruton’s Tyrosine Kinase
46. BCR-ABL Tyrosine Kinase
- Target Disease: Cancer
- Applicant/Assignee: ShanghaiTech University
- Reference: Compounds targeting and degrading BCR-ABL protein and its antitumor application
47. X-linked Inhibitor of Apoptosis Protein (XIAP/IAP)
- Target Disease: Cancer
- Applicant/Assignee: FIMECS
- Reference: Heterocyclic compound
48. Transmembrane 4 L6 Family Member 1 (TM4SF1)
- Target Disease: Cancer
- Applicant/Assignee: Angiex
- Reference: Degrader-antibody conjugates and methods of using same
49. Androgen Receptor (AR)
- Target Disease: Cancer
- Applicant/Assignee: Jiangxi Jemincare Group Co Ltd, Shanghai Jemincare Pharmaceuticals Co Ltd
- Reference: Phthalazinone compound, preparation method, and medical use thereof
Aspirin as a PROTAC and Molecular Glue Antagonist: A Conceptual Exploration Based on Recent Findings
Targeted Protein Degradation in Clinical Trials: The Promise of PROTACs and Molecular Glues Targeted protein degradation (TPD) has emerged as a promising therapeutic approach, with
PROTAC Meets Cell Therapy: Enhancing NK Cell-Based Cancer Immunotherapy Through Targeted Protein Degraders (TPDs)
In a recent study reported in the journal Molecular Therapy, a team led by researchers from the University of Science and Technology of China,
Degrader-Antibody Conjugates (DACs) – Transforming Immunotherapy by Combining Antibody Drug Conjugates (ADCs) and Targeted Protein Degraders (TPDs)
Introduction Degrader Antibody Conjugates (DACs) represent a revolutionary therapeutic modality that combines the precision of monoclonal antibodies (mAbs) with the potent protein degradation capabilities of
Advancing PROTAC Therapeutics: Potency Assays for FDA Compliance
Press Release | Marin Biologic Labs Achieves Flawless FDA Inspection for Second Consecutive Year, Expands Biopharmaceutical Services What are PROTACs? Proteolysis Targeting Chimeric (PROTAC) drugs
Precision in Efficacy: Developing Robust GMP Potency Assays for PROTACs, Molecular Glues, and Other Targeted Protein Degradation (TPD) Drugs
With over 30 years of expertise in cell-based potency assay development, we deliver precise, GMP-compliant potency assays for PROTACs, molecular glues, and other TPD drug
Proteolysis Targeting Chimera’s (PROTAC’s) Path from Innovation to Therapeutic Development: Insights from the Gartner Hype Cycle
With over 30 years of expertise, we specialize in providing assay services essential for targeted protein degradation (TPD) drug development, preclinical studies, IND/BLA applications, and
